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RESUMO
Introdução:  A terapeutica com anti-factor de proliferação endotelial vascular revolucionou o tratamento da degenerescência macular 
da idade exsudativa; no entanto, é importante monitorizar o uso em contexto real do ranibizumab e os resultados associados ao trata-
mento na prática clínica corrente.
Material e Métodos: Este foi um estudo observacional, retrospetivo, para monitorizar os resultados de dois anos, após o tratamento 
com ranibizumab para a da degenerescência macular da idade exsudativa em Portugal. Os doentes tratados entre janeiro de 2009 e 
dezembro de 2009 foram avaliados retrospetivamente. Todas as decisões foram tomadas pelo médico responsável pelo tratamento, 
em conformidade com a respetiva prática clínica corrente. A avaliação primária foi a alteração média na melhor acuidade visual cor-
rigida utilizando a tabela ETDRS (Early Treatment of Diabetic Retinopathy Study) ou Snellen equivalente.
Resultados: Foi analisado um total de 128 doentes com degenerescência macular da idade exsudativa (idade média de 79,4 anos; 
média de acuidade visual de 54,2 letras). A alteração média na melhor acuidade visual corrigida desde a  situação basal foi de -1,6 
letras (n = 82) no ano um e -5,1 letras (n = 72) no ano dois. O número médio de injeções de ranibizumab foi de 3,8 (ano um) e 1,6 (ano 
dois). Em média, os doentes tiveram entre 8,6 e 5,0 consultas e foi utilizada a tomografia de coerência ótica em 75,0% dos doentes no 
ano um e em 56,3% dos doentes no ano dois, respetivamente.
Discussão: Apesar do número de consultas relativamente elevado, incluindo consultas de monitorização e de utilização de terapêu-
tica guiada por tomografia de coerência ótica, foram administradas poucas injeções e não houve melhoria na acuidade visual.
Conclusão: Em Portugal, num contexto real, estes achados indicam que o tratamento consoante as necessidades resultou numa 
dosagem insuficiente. Essas limitações também podem estar associadas ao número crescente de doentes, o que resulta numa satu-
ração clínica.
Palavras-chave: Acuidade Visual; Degenerescência Macular Exsudativa; Factores de Tempo; Portugal; Ranibizumab
ABSTRACT
Introduction: Anti-vascular endothelial growth factor therapy has revolutionized the treatment of wet age-related macular degeneration; 
however, it is important to monitor actual use of ranibizumab and related treatment outcomes in routine practice.
Material and Methods: This was a retrospective, observational study to monitor the 2-year outcomes following ranibizumab treatment 
for wet age-related macular degeneration in Portugal. Patients treated between January 2009 and December 2009 were retrospectively 
evaluated. All decisions were made by the treating physician in accordance with their usual routine clinical practice. The primary 
assessment was mean change in visual acuity score using Early Treatment Diabetic Retinopathy Study or Snellen equivalent.
Results: A total of 128 patients with wet age-related macular degeneration were analyzed (mean age 79.4 years; mean visual acuity 
score 54.2 letters). Mean change in visual acuity score from baseline was –1.6 letters (n = 82) at year one and –5.1 letters (n = 72) at 
year two. The mean number of ranibizumab injections was 3.8 (year one) and 1.6 (year two). On average, patients attended 8.6 and 5.0 
visits and optical coherence tomography was used in 75.0% of patients in year one and in 56.3% of patients in year two, respectively.
Discussion: Despite a relatively high number of visits, including monitoring visits and use of optical coherence tomography - guided 
therapy, few injections were administered and visual acuity was not improved.
Conclusion: These findings indicate that as-needed treatment resulted in under-dosing in a real-life setting in Portugal. Such limitations 
may also be related to increasing numbers of patients, resulting in clinic saturation.
Keywords: Portugal; Ranibizumab; Visual Acuity; Wet Macular Degeneration
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INTRODUCTION
 Anti-vascular endothelial growth factor (anti-VEGF) 
therapy has revolutionized the treatment of wet age-
related macular degeneration (wAMD), and its widespread 
introduction may be associated with a decrease in the 
incidence of legal blindness.1 Intravitreal ranibizumab was 
approved for use in this chronic degenerative condition, 
largely based on the outcomes from the two key registry 
studies (ANCHOR [ANti-VEGF antibody for the treatment 
of predominantly classic CHORoidal neovascularization 
in age-related macular degeneration] and MARINA 
[Minimally classic/occult study of the Anti-VEGF antibody 
Ranibizumab In the treatment of Neovascular Age-related 
macular degeneration]).2,3 In these studies, mean visual 
acuity improved by 11.3 and 7.2 letters, respectively, at 12 
months with monthly use of intravitreal ranibizumab 0.5 mg.
 However, a number of alternative regimens, including 
as-needed dosing, have also been proposed and are 
widely used in clinical practice.4-8 Results from clinical 
studies indicate that outcomes are more variable with less-
frequent intravitreal ranibizumab dosing.9-11 LUMIERE, 
a retrospective observational study of 551 patients with 
wAMD, showed that poor compliance with intravitreal 
ranibizumab was associated with loss of initial treatment 
gains over a 12 - month period, from 5.3 letters at month 
three to 3.2 letters at month 12. In LUMIERE, less than 40% 
of patients received three initial monthly injections, and the 
mean number of injections was 5.1 over the 12 - month 
period.4 
 In another retrospective real-world study (AURA; 
A retrospective non-interventional study to assess the 
effectiveness of existing anti-VEGF treatment Regimens 
in patients with wAMD), the mean change in visual acuity 
decreased from +2.4 letters (year one) to +0.6 letters (year 
two) in patients with wAMD who received an average 
of 5.0 and 2.2 intravitreal ranibizumab injections in year 
one and year two, respectively.6 AURA was conducted in 
eight countries, but did not include Portugal. The aim of 
this study, which was based on the AURA design, was to 
determine the real-life utilization and associated outcomes 
following intravitreal ranibizumab use in wAMD patients 
from Portugal.
MATERIAL AND METHODS
Study design and patients
 This was a retrospective, multicenter, non-interventional, 
observational study (NCT01933152) to monitor the real-
life use and related outcomes following treatment with 
intravitreal ranibizumab for wAMD in patients from clinical 
practices in Portugal (Centro Hospitalar do Porto, Unidade 
Local de Saúde de Matosinhos, Centro Hospitalar de Lisboa 
Norte, Instituto Oftalmológico Gama Pinto and Centro 
Hospitalar e Universitário de Coimbra). We collected data 
retrospectively from medical records of treatment-naïve 
patients who were diagnosed with wAMD and prescribed 
intravitreal ranibizumab between 01 January 2009 and 31 
December 2009. We collected data for up to three years, 
with the final data collection on 30 April 2013 (Fig. 1); 
however, we report only outcomes at year one and year 
two. The 3-year data are not presented due to low follow-up 
at this point. 
 The treating physicians made all diagnoses and 
subsequent decisions to treat (including dose and duration) 
in accordance with their usual routine clinical practice. 
This was based on wAMD treatment guidelines and the 
indication for ranibizumab at the time of the study, which 
included monthly or as-needed dosing after a loading 
phase. All centers used an as-needed regimen, and the 
proportion of patients who received a loading phase was 
recorded. All treating physicians were sufficiently trained 
on the background and objectives of the study, protocol 
and procedures, use of the electronic case report form (to 
collect retrospective data), and ethical as well as regulatory 
obligations. The study was performed in accordance with 
the Declaration of Helsinki (2008). Approval from the 
relevant independent ethics committee was obtained. All 
patients provided written informed consent. Eligible patients 
were documented using the electronic case report form. 
Patients who had participated in an investigational study of 
any other drug or device during the treatment period from 
start to 31 December 2011 were excluded.
Study assessments
 Our primary objective was to evaluate the mean change 
in visual acuity score (VAS) after treatment with intravitreal 
ranibizumab (using ETDRS or Snellen equivalent). 
Secondary objectives were to monitor resource utilization 
(i.e., number of visits [total, clinic, and monitoring] and 
intravitreal ranibizumab injections) after the start of therapy, 
including outcomes from diagnostic tests, and to determine 
the socio-demographic profile of the patients diagnosed 
Figure 1 – Study design and timeline
FPFV: First patient first visit; LPFV: Last patient first visit; LPLV: Last patient last visit; VEGF: Vascular endothelial growth factor.
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with wAMD. We retrospectively evaluated data from 
patient medical records and the results from any routine 
examinations and assessments.
Statistical analyses
 Our study was explorative; there were no formal 
hypotheses. We calculated that a sample size of 200 
patients was needed to estimate, within a 95% confidence 
interval, the change in visual acuity from baseline (based 
on the ETDRS letter score) in patients being treated with 
anti-VEGF therapy with a margin of error of 2.0 letters. A 
standard deviation (SD) of 14.4 for the change in visual 
acuity was assumed based on the values observed for 
ranibizumab 0.5 mg every four weeks in the VIEW 1 and 
VIEW 2 (VEGF Trap-Eye: investigation of efficacy and 
safety in wAMD) studies.12,13
 We used the exposed population (i.e., patients who 
received ≥ 1 intravitreal ranibizumab injection) as the basis 
for our analyses. For change in visual acuity, we used two 
methods of analysis: method one, taking into consideration 
the visit with the information nearest to 360 days, within 
300 and 420 days after the first injection, or the information 
nearest to 720 days, within 660 and 780 days after the first 
injection, and method two, taking into consideration the 
mean change in visual acuity to the mean value observed 
within 300 and 420 days after the first injection or within 660 
and 780 days after the first injection. 
 For the primary outcome (i.e., mean change in VAS), 
if ETDRS letter scores (or equivalent notations) were not 
available, then we converted the approximate Snellen acuity 
equivalent to VAS. When Snellen had no equivalence with 
VAS, we considered the lowest visual acuity. We analyzed 
VAS using observed data (i.e., missing values were not 
replaced) and via a last observation carried forward (LOCF) 
analysis, which accounted for missing data. For analysis 
of mean change in VAS from baseline (date of the start 
of intravitreal ranibizumab therapy or date of diagnosis if 
unavailable) to year one and year two, we used a SIGN 
test (this analysis was not adjusted for missing data). 
Statistical tests were 2-tailed, considering a significance 
level of 5% (p < 0.05). For analysis of secondary outcomes, 
we used frequency tables for categorical variables and 
sample statistics for continuous variables. For all secondary 
analyses, missing values were not replaced, and any 
percentages were calculated based on non-missing values. 
We performed statistical analyses using SAS version 9.2 
(SAS Institute Inc, Cary, North Carolina, USA).
RESULTS
Patients
 We screened a total of 257 patients; however, 129 
patients were not eligible for participation and were excluded 
due to the following reasons: lost to follow-up (n = 76), death 
(n = 32), refusal to participate (n = 10), change of treating 
physician (n = 4), unable to be contacted or had changed 
address (n = 5), unable to provide written informed consent 
Figure 2 – Patient flow diagram
Screened
 (n = 257)
Excluded
 (n = 129)
- Lost to follow-up (n = 76)
- Death (n = 32)
- Refusal to participate (n = 10)
- Change of treating physician (n = 4)
- Unable to be contacted (n = 5)
- Unable to provide written informed consent (n = 1)
- Unable to provide written informed consent / hypoacusis (n = 1)
Enrolled
 (n = 128)
Eligible for analysis
 (n = 128)
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(1), and unable to provide written informed consent and 
presented with marked hypoacusis (1). A total of 128 
patients were enrolled and eligible for analysis (Fig.2). 
The baseline characteristics of the exposed population 
(n = 128) are summarized in Table 1. The mean (SD) 
age was 79.4 (7.9) years and 62.5% were female. Study 
(treated) eye was the right eye for 57.0% of patients and 
the left eye for 43.0% of patients. The mean (SD) time 
from diagnosis to first intravitreal ranibizumab injection 
was 73.4 (220.0) days. The mean (SD) time from first 
injection to last follow-up visit was 712.0 (277.1) days. 
The time in study ranged from 36 – 1072 days.
Change in VAS 
 Using method one, the mean change in VAS (letters) 
from baseline was –1.6 letters (from a mean [SD] score 
of 54.2 [19.6] at baseline [start of therapy or diagnosis] to 
52.6 [22.8]; n = 82) at year one and –5.1 letters (from a 
mean [SD] score of 52.5 [20.4] at baseline to 47.4 [25.0]; 
n =  72) at year two; these changes were not statistically 
significant (p = 0.43 and p = 0.80, respectively) (Fig. 3A). 
Using method two, the mean change in VAS (letters) from 
baseline was –1.98 letters (year one) and –5.11 letters (year 
two). A total of 120 patients were included in the LOCF 
analysis, and the mean change in VAS (using the LOCF 
approach) from baseline was –1.88 letters (year one) and 
–5.56 letters (year two) (Fig. 3B). 
Resource utilization
 Visits: The mean number of clinic visits (when patients 
received treatment), monitoring visits (when patients did not 
receive treatment), and total visits (clinic and monitoring 
visits) attended during year one and year two is shown in 
Fig. 4A. There was a decrease in total visits from 8.6 in year 
one to 5.0 in year two. The mean number of clinic visits was 
low, decreasing from 3.7 (year one) to 1.6 (year two), and 
monitoring visits decreased from 4.9 (year one) to 3.5 (year 
two).
 Injections: The mean number of injections received 
during year one and year two is shown in Fig. 4A. In the 
first year, the mean number of injections administered was 
3.8, decreasing to 1.6 in year two. Within the first 125 days, 
38.3% of patients received three injections (loading phase) 
and 4.7% received four injections. 
 Diagnostic tests: The most commonly used test was 
optical coherence tomography (OCT), used in 75.0% of 
patients in year one and in 56.3% of patients in year two (Fig. 
4B). Most clinics used spectral-domain OCT at diagnosis 
(77.6%), year one (80.2%), and year two (88.9%). Despite 
an initial decrease in subretinal fluid, there was a marked 
increase in physician-reported cases of subretinal fluid from 
29.2% in year one to 39.4% in year two (Table 2). Physician-
reported geographic atrophy on OCT was documented in 
7.1% of patients at diagnosis, 14.1% of patients at year 
one, and 20.6% of patients at year two. Ophthalmoscopy 
showed that vitreous body and optic nerve head findings 
were normal for the majority of patients throughout the 
study (Table 2). Mean intraocular pressure was 16.1 mmHg 
at diagnosis and approximately 14 mmHg for years one and 
two (Table 2).
Reasons for study discontinuation
 Overall, 35 patients discontinued the study. Of these, 
32 patients discontinued due to permanent discontinuation 
of anti-VEGF therapy, and three patients discontinued due 
to other reasons (Table 3). In patients who permanently 
discontinued treatment, the main reason was investigator-
driven criteria (n = 19). When the discontinuation was 
based on a decision taken by the investigator (e.g., not lost 
to follow-up), the main reason for discontinuation of anti-
VEGF therapy (59%) was treatment failure.
Table 1 – Baseline characteristics (exposed population [n = 128])
Characteristic Exposed population
Age, years, mean (SD) 79.4 (7.9)
Sex, n (%)
  Male 48 (37.5)
  Female 80 (62.5)
Eye affected by wAMD, n (%)
  Right 89 (69.5)
  Left 78 (60.9)
FA performed at diagnosis, n (%)
  Yes 74 (57.8)
  No 54 (42.2)
CNV lesion type, n (%) [n = 74]
  Classic 17 (23.0)
  Classic and occult 15 (20.3)
  Occult 27 (36.5)
  Disciform scar 1 (1.4)
  None 2 (2.7)
  Unknown 12 (16.2)
CRT, µM, mean (SD) 245.5 (116.0)
Visual acuity tests, n (%)
  No 7 (5.5)
  Yes 121 (94.5) 
Visual acuity score,* 
letters, mean (SD) [n = 82]
54.2 (19.6)
Intraocular pressure, 
mmHg, mean (SD)
16.1 (3.1)
Concomitant medication, n (%) 98 (76.6)
Concomitant medication indication (> 15%), n (%)
  Arterial hypertension 81 (82.7)
  Dyslipidemia 30 (30.6)
  Diabetes mellitus 21 (21.4)
  Glaucoma 18 (18.4)
  Depression 15 (15.3)
* ETDRS and Snellen at baseline (start of treatment or diagnosis).
CNV: Choroidal neovascularization; CRT: Central retinal thickness; FA: Fluorescein 
angiography; SD: Standard deviation; wAMD: Wet age-related macular degeneration.
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Figure 4 – (A) Mean number of visits and intravitreal ranibizumab injections in year one (≤ 365 days) and year two (> 365 and ≤ 730 days) 
and (B) mean number of diagnostic tests performed in year one and year two in the exposed population (n = 128) 
FA: Fluorescein angiography; ICGA: Indocyanine green angiography; IOP: Intraocular pressure; OCT: Optical coherence tomography.
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Figure 3 – Mean change in visual acuity score from baseline over the 2-year period in the exposed population (A) with no adjustment for 
missing data (n = 128) and (B) using a LOCF approach (n = 120) 
LOCF: Last observation carried forward; VAS: Visual acuity score
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DISCUSSION
 The primary objective of our study was to evaluate 
changes in visual acuity during the first and second years 
after the introduction of anti-VEGF therapy with intravitreal 
ranibizumab in patients from Portugal. The mean change 
in visual acuity from the start of intravitreal ranibizumab 
therapy or diagnosis was –1.6 letters at year one and –5.1 
letters at year two, which were not statistically significant 
compared with baseline. Similar findings were also observed 
using a LOCF approach, where mean changes were –1.9 
letters (year one) and –5.6 letters (year two). On average, 
patients attended 8.6 visits during year one and 5.0 visits 
during year two. The majority of patients underwent OCT 
at year one and year two time points (75.0% and 56.3%, 
respectively). However, the mean number of intravitreal 
ranibizumab injections was very low, with patients receiving 
3.8 injections during year one and 1.6 injections during year 
two. It is noteworthy that the proportion of patients with 
subretinal fluid increased from year one to year two (from 
29.2% to 39.4%). Geographic atrophy was identified in 7.1% 
of patients upon diagnosis, increasing to 20.6% at two years, 
which we might speculate to be related to the underlying dry 
AMD.
 In the global AURA study, the mean change in VAS was 
+2.4 letters (5.0 injections and 8.6 visits) in year one and 
+0.6 letters (2.2 injections and 4.9 visits) in year two using a 
LOCF approach.6 AURA also showed that the mean change 
in VAS was lowest in Italy, where the changes were 0 letters 
(3.8 ranibizumab injections and 8.5 visits) at year one and 
–2.9 letters (1.2 ranibizumab injections and 4.2 visits) at 
year two. The mean change in VAS was highest in the 
UK, where the changes were +6.0 letters (5.8 ranibizumab 
Table 2 – Key outcomes of diagnostic tests performed (exposed population [n = 128])
Test/key outcome Diagnosis Year one Year two
Ophthalmoscopy
  Vitreous body, n (%)
    Normal 60 (98.4) 28 (100.0) 27 (96.4)
    Abnormal 1 (1.6) 0 1 (3.6)
  Optic nerve head, n (%)
    Normal 48 (100.0) 18 (94.7) 18 (90.0)
    Abnormal 0 1 (5.3) 2 (10.0)
OCT
  CRT, µm, mean (SD)
245.5 (116.0)
[n = 14]
213.6 (39.1)
[n = 11]
180.0 (76.4)
[n = 2]
  Total volume, mm2, mean (SD)
9.6 (2.6)
[n = 75]
9.2 (1.7)
[n = 65]
8.8 (1.9)
[n = 54]
  Subretinal fluid, n (%)
    No 49 (47.6) 63 (70.8) 43 (60.6)
    Yes 54 (52.4) 26 (29.2) 28 (39.4)
  Geographic atrophy, n (%)
    No 91 (92.9) 73 (85.9) 50 (79.4)
    Yes  7 (7.1) 12 (14.1) 13 (20.6)
Fluorescein angiography
  Area of total lesion, mm2, mean (SD)
28.5 (23.1)
[n = 42]
25.7 (29.9)
[n = 6]
1.8 (0.5)
[n = 2]
  Area of CNV, mm2, mean (SD)
14.5 (14.5)
[n = 22]
48.1 (52.1)
[n = 2]
1.8 (0.5)
[n = 2]
Indocyanine green angiography
  PCV, n (%)
    No 35 (87.5) 0 0
    Yes 5 (12.5) 2 (100.0) 1 (100.0)
  RAP, n (%)
    No 32 (78.0) 2 (100.0) 1 (100.0)
    Yes 9 (22.0) 0 0
Intraocular pressure
  Intraocular pressure, mmHg, mean (SD)
16.1 (3.1)
[n = 32]
14.3 (3.7)
[n = 14]
14.2 (2.4)
[n = 11]
CNV: Choroidal neovascularization; CRT: Central retinal thickness; OCT: Optical coherence tomography; PCV: Polypoidal choroidal vasculopathy; RAP: Retinal anastomoses 
proliferation; SD: Standard deviation.
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injections and 10.4 visits) at year one and +4.1 letters (3.2 
ranibizumab injections and 8.0 visits) at year two.6
 In our study, visual acuity declined over a 2-year follow-
up period. These findings are generally consistent with a 
smaller Portuguese observational study of 77 patients 
with wAMD (84 eyes) who were treated with intravitreal 
ranibizumab over a 3-year period.14 At three years, the 
mean number of treatments was 8.6, but improvements 
in visual acuity were not maintained over time as only 
15.4% presented a gain of ≥ 15 letters in BCVA and 61.5% 
experienced stabilization of BCVA loss (i.e., visual loss of < 5 
letters). In the COMPASS study, which was an observational 
study of 1729 evaluable patients with wAMD in Germany, 
patients received 4.5 injections (three injections during a 
3-month loading phase and 1.5 additional injections during 
a 12-month maintenance phase) over a 15-month period, 
and despite initial gains during the loading phase, patients’ 
visual acuity declined thereafter.7 These authors argued that 
a flexible and predominantly visual acuity-driven retreatment 
regimen results in a loss of visual acuity, which is consistent 
with other studies.15 Although our study showed this decline 
in visual acuity over time, there were very little initial gains 
compared with other observational studies, which may 
be related to the lack of a loading phase, with less than 
50% of patients receiving three injections during the first 
125 days, and low number of injections overall. It must also 
be noted that there was a delay between diagnosis and 
start of treatment; the mean time was 73.4 days. Although 
the reasons for this are not known, and may be related to 
patient choice, referral, or reimbursement issues, this delay 
may have affected outcomes.
 The treatment outcomes in our study were also less 
favorable than those observed in randomized clinical trials. 
In CATT (Comparison of Age-related macular degeneration 
Treatments Trial), 1107 patients with wAMD were 
randomized to intravitreal ranibizumab or bevacizumab and 
followed over a 2-year period.16 The mean gain in letters 
at year two was greater with monthly than with as-needed 
treatment (+8.8 letters vs +6.7 letters, respectively). The 
mean number of injections was 22.4 with monthly and 
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12.6 with as-needed treatment over the 2-year period. In 
ANCHOR, the mean change in letters was +11.3 letters 
at year one and +10.7 letters at year two, and the mean 
number of intravitreal ranibizumab injections was 21.3 over 
the 2-year period.2 In MARINA, mean change in letters was 
+7.2 letters (year one) and +6.6 letters (year two) (based 
on ≤ 24 intravitreal ranibizumab injections over the 2-year 
period).3
 We note that our study has a number of limitations 
inherent to its retrospective and observational design. 
Our study also failed to reach the target population of 
200 patients. Clinical practice may have changed since 
the study was undertaken, and VAS was monitored using 
different methods. 
CONCLUSION
 In summary, on average, few injections were 
administered and visual acuity was not improved during 
the 2-year follow-up in a cohort of patients with wAMD 
enrolled in our study. Despite a relatively high number of 
visits, including monitoring visits and use of OCT-guided 
therapy, the findings indicate that as-needed treatment 
with intravitreal ranibizumab resulted in suboptimal visual 
acuity in real-life settings. Such limitations may also be 
related to an increased number of wAMD patients resulting 
in clinic saturation coupled with funding constraints within 
the Portuguese health care system. These limitations are 
consistent with those published by the Royal College of 
Ophthalmologists,17 which advises that patients requiring 
long-term follow-up and regular specialist treatment will 
cause a capacity problem for a health care system, and 
that a number of approaches may be needed to address 
the wAMD bottleneck. Tailored advice regarding effective 
working models for the long-term management of wAMD 
patients in clinical practice is warranted.
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Table 3 – Reasons for study discontinuation (exposed population [n = 128])
Reasons Exposed population
Study completers 93 (72.7)
Discontinuations
  Permanent discontinuation of anti-VEGF therapy 32 (25.0)
  Withdrawal by patient 1 (0.8)
  Other 2 (1.6)
Reasons for permanent discontinuation of anti-VEGF therapy, n (%) [n = 32]
  Investigator-driven criteria 19 (59.4)
  Other 13 (40.6)
Drug switching, n (%) [n = 32]
  Bevacizumab 1 (3.1)
  Photodynamic therapy 1 (3.1)
VEGF: Vascular endothelial growth factor
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